Challenges and Strategies for Implementing Automated Visual Inspection for Biopharmaceuticals - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Challenges and Strategies for Implementing Automated Visual Inspection for Biopharmaceuticals
The authors used a light-transmission-based static division system to detect particles of foreign contaminants in prefilled vials.

Pharmaceutical Technology

Methods and materials

Eisai Automated Inspection Machine (Model 587-2, Eisai Machinery of USA, Allendale, NJ) was used to conduct an automated inspection. Mimic solutions were prepared by adding an estimated amount of PEG 1000 into desired buffer solution to reach a target viscosity value. Upon proper mixing, a sample was tested for viscosity confirmation. The mimic solution was then filtered through a 0.22μm filter and aspectically filled into vials followed by manual inspection to ensure absence of foreign particles. These clean vials were spiked with standard glass beads of three different sizes: 70μm, 100μm and 400μm (Duke Scientific Soda Lime Glass, Palo Alto, CA). Each vial was seeded with a single glass bead. The seeded vials were manually inspected a second time to ensure that each vial only had one particle and no other foreign contaminants. Two different buffer formulations (with and without polysorbate) were used to prepare PEG solutions of different viscosities. Formulations comprised of a commonly used stabilizing excipient (sucrose or sorbitol) and a buffering agent (acetate). The formulations are listed as follows and are referred to accordingly in the remaining sections of this article:

Formulation A = PEG 1000 in acetate buffer + sucrose + Polysorbate 20

Formulation B = PEG 1000 in acetate buffer + sorbitol

Experimental design. Vials seeded with particles were inspected on the Eisai machine through a double-check system comprising two inspection stations. A set of 24 vials (six clean and six each seeded with 70μm, 100μm and 400μm particles) were inspected at each inspection station. Each vial was inspected 32 times in a single run. A total of three runs were conducted to estimate statistical error in the performance. For selected experiments, a design of experiment (DOE) was performed using a space-filling design and spanning a range of spin and brake settings for a fill configuration of 1.7 mL in 3 cc. All DOE experiments were conducted for solutions with different viscosities using PEG solution in Formulation B.

Data analysis. Inspection data obtained from the Eisai AIM were analyzed by calculating the detection rate (%DR) as follows:

The detection rate can then be calcuated for each vial type (clean, 70μm, 100μm and 400μm) by averaging the %DR values for all six vials in each group. For runs that were conducted in triplicates, the average and standard deviation were also computed for the detection rate for each particle size. For the data generated through DOEs, contour plots were generated to depict detection rates for 400 μm-particle size at various spin and brake settings.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here